Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress (original) (raw)
Dock G (1904) Influence of complicating diseases upon leukemia. AM J Med Sci127: 563–592 Article Google Scholar
Bierman HR et al. (1953) Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer6: 591–605 ArticleCASPubMed Google Scholar
Bluming AZ and Ziegler JL (1971) Regression of Burkitt's lymphoma in association with measles infection. Lancet2: 105–106 ArticleCASPubMed Google Scholar
DePace NG (1912) Sulla Scomparsa di un enorme cancro begetante del callo dell'utero senza cura chirurgica [Italian]. Ginecolgia9: 82 Google Scholar
Hansen RM and Libnoch JA (1978) Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch Intern Med138: 1137–1138 ArticleCASPubMed Google Scholar
Shimizu Y et al. (1988) Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. Cancer Detect Prev12: 487–495 CASPubMed Google Scholar
Milton GW and Brown MM (1966) The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. Aust N Z J Surg35: 286–290 ArticleCASPubMed Google Scholar
Hunter-Craig I et al. (1970) Use of vaccinia virus in the treatment of metastatic malignant melanoma. BMJ2: 512–515 ArticleCASPubMed Google Scholar
Arakawa S Jr et al. (1987) Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma: report on two cases. J Cancer Res Clin Oncol113: 95–98 ArticlePubMed Google Scholar
Gomella LG et al. (2001) Phase I study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol166: 1291–1295 ArticleCASPubMed Google Scholar
Roenigk HH Jr et al. (1974) Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol109: 668–673 ArticlePubMed Google Scholar
Kawa A and Arakawa S (1987) The effect of attenuated vaccinia virus AS strain on multiple myeloma: a case report. Jpn J Exp Med57: 79–81 CASPubMed Google Scholar
Mastrangelo MJ et al. (1995) A pilot study demonstrating the feasability of using intratumoral vaccinia injections as a vector for gene transfer. Vaccine Res4: 55–69 Google Scholar
Everall JD et al. (1975) Treatment of primary melanoma by intralesional vaccinia before excision. Lancet2: 583–586 ArticleCASPubMed Google Scholar
Southam CM and Moore AE (1952) Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer5: 1025–1034 ArticleCASPubMed Google Scholar
Okuno Y et al. (1978) Studies on the use of mumps virus for treatment of human cancer. Biken J21: 37–49 CASPubMed Google Scholar
Wheelock EF and Dingle JH (1964) Observations on the repeated administration of viruses to a patient with acute leukemia: a preliminary report. N Engl J Med271: 645–651 ArticleCASPubMed Google Scholar
Cassel WA and Garrett RE (1965) Newcastle Disease Virus as an antineoplastic agent. Cancer18: 863–868 ArticleCASPubMed Google Scholar
Csatary LK et al. (1993) Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev17: 619–627 CASPubMed Google Scholar
Csatary LK and Bakacs T (1999) Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA281: 1588–1589 ArticleCASPubMed Google Scholar
Csatary LK et al. (2004) MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neuro-oncol67: 83–93 ArticleCAS Google Scholar
Kirn D et al. (2001) Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med7: 781–787 ArticleCASPubMed Google Scholar
Pecora AL et al. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol20: 2251–2266 ArticleCASPubMed Google Scholar
Lorence RM et al. (2003) Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther5: 618–624 CASPubMed Google Scholar
Freeman AI et al. (2006) Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther13: 221–228 ArticleCASPubMed Google Scholar
Morris DG et al. (2002) A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies [abstract # 92]. Proc Am Soc Clin Oncol21: a24 Google Scholar
Kirn D (2001) Clinical research results with _dl_1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther8: 89–98 ArticleCAS Google Scholar
Morley S et al. (2004) The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res10: 4357–4362 ArticleCASPubMed Google Scholar
Mulvihill S et al. (2001) Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther8: 308–315 ArticleCASPubMed Google Scholar
Nemunaitis J et al. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res60: 6359–6366 CASPubMed Google Scholar
Ganly I et al. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res6: 798–806 CASPubMed Google Scholar
Nemunaitis J et al. (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol19: 289–298 ArticleCASPubMed Google Scholar
Chiocca EA et al. (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther10: 958–966 ArticleCASPubMed Google Scholar
Vasey PA et al. (2002) Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol20: 1562–1569 CASPubMed Google Scholar
Makower D et al. (2003) Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res9: 693–702 PubMed Google Scholar
Reid T et al. (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res62: 6070–6079 CASPubMed Google Scholar
Habib NA et al. (2001) E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther12: 219–226 ArticleCASPubMed Google Scholar
Habib N et al. (2002) Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther9: 254–259 ArticleCASPubMed Google Scholar
Nemunaitis J et al. (2001) Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther8: 746–759 ArticleCASPubMed Google Scholar
Hamid O et al. (2003) Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol21: 1498–1504 ArticleCASPubMed Google Scholar
Khuri FR et al. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med6: 879–885 ArticleCASPubMed Google Scholar
Yuan ZY et al. (2003) Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer [Chinese]. Ai Zheng22: 310–313 PubMed Google Scholar
Lu W et al. (2004) Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol10: 3634–3638 ArticleCASPubMedPubMed Central Google Scholar
Xia ZJ et al. (2004) Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus [Chinese]. Ai Zheng23: 1666–1670 PubMed Google Scholar
DeWeese TL et al. (2001) A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res61: 7464–7472 CASPubMed Google Scholar
Small EJ et al. (2006) A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther14: 107–117 ArticleCASPubMed Google Scholar
Markert JM et al. (2000) Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther7: 867–874 ArticleCASPubMed Google Scholar
Kemeny M et al. (2006) Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther17: 1214–1224 ArticleCASPubMed Google Scholar
Mastrangelo MJ et al. (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther6: 409–422 ArticleCASPubMed Google Scholar
Hu JC et al. (2006) A phase I clinical trial with OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res12: 6737–6747 ArticleCASPubMed Google Scholar
Freytag SO et al. (2002) Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res62: 4968–4976 CASPubMed Google Scholar
Freytag SO et al. (2003) Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res63: 7497–7506 CASPubMed Google Scholar
Laurie SA et al. (2006) A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res12: 2555–2562 ArticleCASPubMed Google Scholar
Hotte SJ et al. (2003) Slow intravenous infusion of PV701, an oncolytic virus: final results of a phase I study [abstract # 3037]. Proc Am Soc Clin Oncol22: s14s Google Scholar
Horstmann E et al. (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med352: 895–904 ArticleCASPubMed Google Scholar
Hecht JR et al. (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res9: 555–561 CASPubMed Google Scholar
Galanis E et al. (2005) Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther12: 437–445 ArticleCASPubMed Google Scholar
Reid T et al. (2001) Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther8: 1618–1626 ArticleCASPubMed Google Scholar
Nemunaitis J et al. (2003) Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther10: 341–352 ArticleCASPubMed Google Scholar
Wein LM et al. (2003) Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res63: 1317–1324 CASPubMed Google Scholar
Rampling R et al. (2000) Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther7: 859–866 ArticleCASPubMed Google Scholar
Papanastassiou V et al. (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther9: 398–406 ArticleCASPubMed Google Scholar
Harrow S et al. (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther11: 1648–1658 ArticleCASPubMed Google Scholar
MacKie RM et al. (2001) Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet357: 525–526 ArticleCASPubMed Google Scholar